retired
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CRIS up 10%. A great risk/reward play.
Hi Greenie, I am also long BAC, based on the story that a fund manager who was consistently short banks prior to march and who is now long many bank issues. Supposedly he has a large position in BAC. Why have you chosen to buy BAC?
TSPT's chief molecule is a sublingual version of zolpiderm. The tablet form Ambien has been around for 10 or more years. What is the market for the sub version? Is this really going to be a big money maker?? Like Dew says If they make 50mil a year it will be pushing it.
MEDX - BMY deal likely etched in stone. If you have a profit take it! Courtesy of joyost3 at yahoo:
you need to read that press release again. It's a done deal at $16.00.
They've already SIGNED the agreement. It's not open to other offers at this point. And I'm sure that other offers were sought before taking the deal. All it needs now is the formality of stockholders approve and federal approval. And they would have gotten majority approval verbally from the major stockholders before signing the deal.
And it could die in federal approval, so take the $15.88 now. It's not worth waiting months for a gain of only pennies.
Croumagnon, of course unload your calls and take the profit. If you feel there may be competing offers then buy a smaller amount of 15calls, further out months of course.
Oh yeah, I forgot about the scandalous issue AJT uncovered. We better not mention it further lest they close down this board too. Of course, we could all abandon this site and move to a more reputable one like Investorsvillage...
OT: Investorshub is going about it the wrong way. AJT's board used to be lively but now that it's a "premium" board its a dead zone. This is a real quick way to kill a board and a website.
Wow, what a shock to hear of Airdales's passing. What can I say but that it had been a real privilege and pleasure to read Airdale's astute analysis of the markets. My heartfelt condolences to his family. Airdale will be greatly missed!
IVN up 4%. What gives? Stability agreement getting finalized with the Mongols?
Airedale, at TraderTalk, you projected a downside target for the SPX fo 1456, provided certain criterias were met. Is this target still valid or has your work come up with a different scenario for the short term? TIA.
DNDN - The Light bulb went off...? Any opinions, not about the medical aspects but the possible short squeeze that could propel DNDN shares to the stratosphere, whether deserved or not?-Profit_ace
DNDN - The light bulb went off in someone's head on Wall Street on Thursday...
http://www.investorvillage.com/smbd.asp?mb=971&pt=msg&mn=67348
By: skcotswonki
The light bulb went off in someone's head on Wall Street on Thursday...
Someone on Wall Street took a careful look at DNDN on Thursday morning, and like the ship captain in the Poseidon Adventure they looked out and saw the coming tsunami and said "OH MY GOD, turn on those buy programs now, TURN THEM ON!"
Some of the shorts will go bankrupt and will be out of business before this is over.
Stocks are not supposed to do what DNDN did on Thursday, ever. The jump last Friday and the 92 million share day were predictable if Provenge received a strong endorsement from the advisory committee, which it did. Stocks that jump on news are supposed to see their volume decline about in half each of the next several trading days as the story runs out of legs and normal trading resumes. Volume in DNDN fell to 13 million shares on Wednesday. This is exactly what DNDN was doing until about one hour into trading on Thursday, then someone on Wall Street hit the panic buy button.
DNDN went on to trade 60 million shares on Thursday and climb almost 20% on no new news, no analyst upgrades, no events at all that should have caused the stock to trade more than 10 million shares on a get out of town day before the three day weekend.
Now, why has it taken a week for what is about to happen to soak in to someone' mind with access to the buy button on Wall Street? First, and remember this, this has never happened before in this way in the history of Wall Street. You have never had such a leveraged bet to the downside that was so incredibly stupid and wrong going into an event that has almost unlimited upside without the shorts, a chance to own some of the only 82 million shares in the world of the company with the biggest breakthrough in cancer since surgery and radiation. Second, and equally important, you have never had such corrupt and lopsided and wrong analysis passed off as research since probably the late 1920's. Hence, there is not a single research report someone on Wall Street can pick up and read and say WOW, Provenge is a $2 billion plus drug and DNDN is worth 5 to 20 times that $2 billion figure, discounted back for risk and time. That discounted value is triple digits in and of itself. The analysts were still out screaming in the press on Friday and Monday that the FDA would not approve what their advisory panel just voted overwhelmingly to approve, now that's corrupt.
On Thursday, when the buy button was hit on the buy program, it quickly took out an unprepared line of defense at $15.40. The shorts attempted to regroup at $15.88, $16, $16,72, and $17. All of these lines of defense were quickly over-run and the buying program marched straight to $18. This is where the shorts were able to regroup and throw everything they had to stop the wave. However, the only thing they have left to fight with is MORE NAKED SHORTING. So, at the end of the day, net-net, there may actually have been an increase in the short position because of the three hour and 40 million share fight Thursday afternoon to defend or breakthrough $18.
Now, if you have not fully comprehended what I have just written in setting the stage, then stop here and go back and re-read it before you move on to read about the coming Tsunami and the light bulb that went off in some Wall Street Captains head.
First, this person realized that the ASS (Ashcoff, Shenouda, & Sendek) team of analysts are lying. The FDA will 100% not keep Provenge off the market to run the 9902B study, that's right I said 100%. The only risk to approval by May is the CMC section (which is so far so good), or some excuse like working on the safety plan so that the FDA can approve Provenge subject to a 90 day delay which would really be about finishing enrollment in 9902B by mid summer. I give the odds of approval in May 98% and the odds of approval in 2007 99.98%. This Wall Street Captain knows approval of a billion dollar cancer drug in a now small cap company is only weeks away, maybe only days away.
Second, the stock is so heavily shorted that almost every brokerage firm on Wall Street has a negative imbalance (naked short) position. This means in a couple of days, if the brokerage firm does not come into balance by locating more shares to borrow or by buying back DNDN to close out the imbalance, then the brokerage firm can not sell more stock short without first having the shares borrowed in advance or having a stock certificate in advance. No more sell today and I will come up with my certificate or borrowed shares on Tuesday. It will all be C.O.D. for the short side. Now, it is a mistake to think the naked short position has to be covered next week, it does not. It is just that no new shorting in size can occur until DNDN comes off the Reg SHO list. The shorts have lost CNBC, their analyst henchmen have lost all credibility and will not be quoted with nonsense like no approval in any stories going forward, and it will keep seeping in on Wall Street that approval is in the bag and Provenge is a multi-billion dollar drug. My guess is over 30 million shares were still sold short at the close of business on Thursday.
Now, again, go back and re-read before moving forward if you didn't fully comprehend what was just written. The Provenge story is a triple digit story. Unwinding the short position in DNDN is a second triple digit story on its own.
There is a third independent triple digit story which is exploding now and will keep exploding over the next few weeks. The call options for April and May are going to be exercised en masse. Today, there are over 25 million April and May options to buy DNDN stock at $10 or less. Most of these deep in the money calls will be exercised and not sold and the market makers and call sellers must deliver over 20 million shares to the owners of these calls in the next few weeks. And because of Reg SHO they can not deliver phantom shares. This is no OSTK people, this is the biggest story on Wall Street and all eyes are on it. The SEC knows it and every compliance department knows it on the Street.
The fourth independent triple digit wave that may hit DNDN is all of the other call options that may soon be deep in the money for April and May followed by all of the August call options. There are over 8 million more April and May calls written at $12 1/2 and $15 that are now deep in the money and will be much deeper when this stock rolls into the mid 20's next week. There are over 5 million August calls that are deep in the money now.
DNDN was the second most active stock in the market on no news on Thursday. DNDN was the 6th largest gainer on no new news on Thursday. Some Wall Street Captain chose to hit the panic buy button on Thursday. Everyone on Wall Street will want to figure out just what the guy who hit the panic buy button knows come early Monday morning.
What he knows is economics 101, supply and demand. There is tremendous demand over the next several days and weeks for shares of DNDN and there are not nearly enough shares to satisfy demand. DNDN is right now in the early stages of hits parabolic run, not the late stages. There has never been three separate triple digit per share circumstance in one stock in the history of Wall Street before. Well, there is now baby, there is now. Forget the fundamentals, this is now all about froth and survival.
If you want to see $100 by May, then do not sell a single share next week. If you have margin, then move some of the DNDN shares that are no longer needed to support the margin account to the cash account (remember it is not an all or nothing proposition). If you own calls at $10 or less for April, then exercise them this week (you don't want to miss the big run and you don't want to pay ordinary gains anyway). If you can, buy more shares or start buying some of the November out of the money calls. The reason so many calls exist is because they are way to cheap and enticing. They will have to price the calls to a point where you think it is 50/50 to buy the calls or buy the stock, or the swelling call volume will not cease.
Everyone have a great Easter weekend and remember the heart of the Christian message is forgiveness. I believe the shorts will see enough punishment for there crimes and it will be so brutal no one with a memory will dare do what they did until the memory of this generation dies out. I am going to spend the weekend conditioning my heart to find compassion for the shorts. Lord knows they need it.
P.S. I do not have access to all of the different hedge fund agreements, but it could be that some of the hedge fund clients actually have liability if the hedge fund goes belly up. If you have a hedge fund find out if they have DNDN shares on the short side Monday morning and if they do, demand your money back immediately, while you still can.
any news on AGIX??
Well, at 6:39 EST IB finally facilitates Globex trading.
I am using IB. This is rotten :(
Doesnt Globex start trading at 6pm EST? Or is IB crashing again? Anybody have same problem?
Anybody playing TELK? Looks like they will be releasing 3
Phase 3 trial data before the end of this year for Ovarian cancer, lung cancer and blood disorder. The upside/downside could be huge here. Anybody have informed opinion of which way the trial will go? TIA. Btw, the near term option premiums are naturally very pricey.
IVN up nearly 20% Stability agreement with Mongolian govt about to be signed?
2Mar$, you playing tonites RIMM earnings? And if so which way are you leaning?
ES options expire samely as SPX options? Anybody know? Like they cease trading after thursday. Are they still exercisable on friday? TIA
Hey Dan, throw me an offer I cant refuse <gg>. Since you specialize in PM, do you think XAU will take off soon,like Monday? I got into some April calls last Thursday and took 1/2 profits the same day(hence I aced it!) but hope to see more green real soon.
Does any esteemed poster know why we didnt get release of the jobs number on Friday??
IVGN reports A/H. Last quarter it lost 12 points! Since then the chart has been constructive. 75calls and 65 puts relatively cheap at .80 and .70.
Thank you rfj..that is very helpful!
Pardon my ignorance. But what does the "ST" in non-ST elevation myocardial infarction stand for? Stent? TIA
Yep, room still down at 9:23 EST
We need to be aware of these new weekly OEX and SPX options, especially if you use IB. I thought I was buying the regular monthly expired Nov. OEX 550 puts (thought they were awfully cheap)but instead got the weekly expired variety. On IB there was no way to discern what one was getting. IB is gonna hear about this! Anybody else having same problem?
Bot a small position of GENZ 70 calls. Will not hedge with puts. If DNA is any indication, GENZ should do well again.
DC, what ya think of GENZ? Reports tomorrow. Went 10 pts higher last earnings. options relatively cheap.
CVT-E002 (Cold-fX®)is currently only available in Canada. The manufacturer is CV Technology (CVQ.V). Hopefully they will have a US listing soon. This article is courtesy RXpress, a pharmacy journal
CVT-E002 (Cold-fX®) claims to boost the immune system
increasing resistance to disease, help prevent colds and flu from
developing, and facilitate rapid recovery. The active component of
CVT-E002 is proprietary extract derived from Panax quinquefolium
(North American ginseng) containing oligosaccharides and
polysaccharides (furanosyl-pyranosyl-saccharides). The
mechanism of action of Cold-fX has been defined via scientific
investigation.
CVT-E002 enhances innate immune responses by activation of and
increasing natural killer (NK) cells (involving a major
histocompatibility complex [MHC] class I mechanism). It also
enhances acquired immune responses (humoral and cellmediated)
as demonstrated by: an increase in interleukins -1 and
-6 (IL -1, IL -6) resulting in proliferation of B- and T- cells, an
increase in circulating IgG (the main antibody defense against
bacteria), and an increase in interleukin-2 (IL-2) and interferongamma
(IFN-gamma) regulators of cell-mediated immunity
(Diagram 1). CVT-E002 does not affect major liver enzymes.20,21
Clinical studies have shown CVT-E002 to be safe and effective
including a successful US FDA randomized double-blind placebocontrolled
trial. In all studies the product was shown to be safe
and well tolerated.
One study concluded that CVT-E002 prevents recurrent cold and
flu infections by 56 per cent and significantly reduces days of
illness and symptom severity. This Health Canada authorized
randomized, double-blind, placebo-controlled trial was conducted
on 279 healthy adults from the general population (18 to 65 years
of age) with a history of at least two upper respiratory infections
(colds) in the previous year. The control group received CVT-E002
(2 X 200 mg/day) for four months and demonstrated a significant
reduction (26 per cent) in the average number and frequency of
upper respiratory infections per person versus placebo. The
incidence of recurrent infections was reduced by 56 per cent. A
reduction in the total number of days suffered with cold or flu
symptoms reduced from 10.9 to 6.0, and a 31 per cent reduction
in the severity of symptoms was observed in the CVT-E002 group.
CVT-E002 was shown to significantly stimulate the total number
of T-lymphocytes and T-helper lymphocytes, as well as Natural
Killer (NK) cells.22,23
Another study demonstrated CVT-E002 reduces
risk of colds, flu and respiratory illness by 89 per
cent and was complimentary to the flu vaccine.
This US FDA authorized randomized doubleblind,
placebo-controlled trial of CVT-E002 in
institutionalized older adults, demonstrated
CVT-E002 significantly reduced the risk, by 89
per cent, of developing laboratory confirmed
influenza or respiratory syncytial virus (RSV) in
a senior population after eight to 12 weeks of
treatment. The control group received a dose of
400 mg daily (2 X 200 mg) of CVT-E002 which
was shown to be effective for preventing acute
respiratory illness due to influenza and RSV.24 A
double-blind, placebo controlled study of CVTE002
in an immunocompetent community
dwelling of adults aged 65 years or older
demonstrated a statistically significant reduction
in the number of illnesses, the majority of which
were associated with respiratory symptoms. The
results demonstrated a greater incidence of
respiratory symptoms in the placebo group (76
per cent) versus the CVT-E002 (45 per cent)
after four months of treatment at 400mg (2 X
200mg) of CVT-E002 ) daily.25
An open study on 22 high performance athletes
demonstrated that 71 per cent reported CVTE002
prevented the cold from developing and
improved how the participants felt with chronic
treatment with CVT-E002. Participants took 400
mg (2 X 200 mg) daily for eight months. Fifty
per cent reported that CVT-E002 allowed them
to recover faster from a cold after three days of
acute treatment at the onset of cold and flu like
symptoms. In the case of acute treatment the
athletes took 600 mg (3 X 200 mg) three times
daily (TID) on day one totaling nine capsules,
then took 400 mg (2 X 200 mg) TID on day two
totaling six capsules, and 200 mg (1 X 200 mg)
TID on day three totaling three capsules.26
The suggested dose of CVT-E002 (Cold-fX®) for
immediate relief is three capsules TID (nine
capsules) on day one, two capsules TID (six
capsules) day two, and one capsule TID (three
capsules) day three. The recommended dose for
daily prevention is one capsule, twice daily.27
While more research is warranted for these
natural products, promising preliminary
investigations have demonstrated positive
clinical conclusions and dosing
recommendations.
CADA rocks, well done Jkool!
Thx patient eom
Good job Nimble...keep those plays coming :)
Anybody playing MSTR? A 65 strangle costs about $10. Any opinion which way MSTR will go after earnings tonite?
SGTL a dud, sold calls for a marginal loss. CADA does look good!
SGTL bottomed around 15.50 and has run up nicely ahead of earnings on Tuesday. I have the 20 calls and is thinking of holding thru earnings. SGTL of course supplies AAPL and we know AAPL had an amazing quarter.
MOH, bounce play. In at 22.80. Few stocks stay down more than $20 in a day.
DC, you da man! what a collar with PDLI. Any gems for next week? So many..cant begin to sort. A few I am researching more on are SEPR FISV FLIR .
Jkool, I am with you bro. I bot the SHLM July 17.5 puts for $0.30. Hope for at least a double :))
Chatroom is working again!
well, can always go to MIRC, using server Othernet and room #gemmer